These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 38797784)

  • 1. Bioinformatics analysis and experimental validation of m6A and cuproptosis-related lncRNA NFE4 in clear cell renal cell carcinoma.
    Feng R; Li H; Meng T; Fei M; Yang C
    Discov Oncol; 2024 May; 15(1):187. PubMed ID: 38797784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cuproptosis-Associated lncRNA Establishes New Prognostic Profile and Predicts Immunotherapy Response in Clear Cell Renal Cell Carcinoma.
    Xu S; Liu D; Chang T; Wen X; Ma S; Sun G; Wang L; Chen S; Xu Y; Zhang H
    Front Genet; 2022; 13():938259. PubMed ID: 35910212
    [No Abstract]   [Full Text] [Related]  

  • 3. Development and validation of a novel 5 cuproptosis-related long noncoding RNA signature to predict diagnosis, prognosis, and drug therapy in clear cell renal cell carcinoma.
    Chen Y; Hu W; Wei X; Zhang L; Shao Y; Tian J; Wang D; Wu B
    Transl Androl Urol; 2023 Apr; 12(4):622-641. PubMed ID: 37181235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of an m6A-Related lncRNA Signature for Predicting the Prognosis in Patients With Kidney Renal Clear Cell Carcinoma.
    Yu J; Mao W; Sun S; Hu Q; Wang C; Xu Z; Liu R; Chen S; Xu B; Chen M
    Front Oncol; 2021; 11():663263. PubMed ID: 34123820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The LncRNA signature associated with cuproptosis as a novel biomarker of prognosis in immunotherapy and drug screening for clear cell renal cell carcinoma.
    Zhang L; Di L; Liu J; Lei X; Gu M; Zhang W; Wang Y
    Front Genet; 2023; 14():1039813. PubMed ID: 36755568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel cuproptosis-related LncRNA signature: Prognostic and therapeutic value for acute myeloid leukemia.
    Li P; Li J; Wen F; Cao Y; Luo Z; Zuo J; Wu F; Li Z; Li W; Wang F
    Front Oncol; 2022; 12():966920. PubMed ID: 36276132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cuproptosis-related LncRNAs are potential prognostic and immune response markers for patients with HNSCC via the integration of bioinformatics analysis and experimental validation.
    Zhou L; Cheng Q; Hu Y; Tan H; Li X; Wu S; Zhou T; Zhou J
    Front Oncol; 2022; 12():1030802. PubMed ID: 36620545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive Analysis of N6-Methylandenosine-Related lncRNAs in Clear Cell Renal Cell Carcinoma: A Correlation With Prognosis, Tumor Progression, and Therapeutic Response.
    Meng C; Li J; Wang X; Ying Y; Li Z; Wang A; Li X
    Cancer Invest; 2024 Apr; 42(4):278-296. PubMed ID: 38644691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Construction and validation of a cuproptosis-related lncRNA signature as a novel and robust prognostic model for colon adenocarcinoma.
    Xu M; Mu J; Wang J; Zhou Q; Wang J
    Front Oncol; 2022; 12():961213. PubMed ID: 35965536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of Critical N6-Methyladenosine-Related Long Non-Coding RNAs and Their Correlations with Immune Checkpoints in Renal Clear Cell Carcinoma.
    Deng W; Wang G; Deng H; Yan Y; Zhu K; Chen R; Liu X; Chen L; Zeng T; Fu B
    Int J Gen Med; 2021; 14():9773-9787. PubMed ID: 34934351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance and immune landscape of cuproptosis-related lncRNAs in kidney renal clear cell carcinoma: a bioinformatical analysis.
    Li D; Wu X; Song W; Cheng C; Hao L; Zhang W
    Ann Transl Med; 2022 Nov; 10(22):1235. PubMed ID: 36544675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive Analysis of N6-Methyladenosine-Related IncRNAs Prognostic Signature and the Associated Immune Infiltrates in Kidney Renal Clear Cell Carcinoma.
    Chen X; Wang L; Tu J; Pan X; Li Y; Yin H; Wang M; Yuan X
    Crit Rev Eukaryot Gene Expr; 2022; 32(1):79-98. PubMed ID: 35377983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N6-Methyladenosine-Related Long Non-coding RNA Signature Associated With Prognosis and Immunotherapeutic Efficacy of Clear-Cell Renal Cell Carcinoma.
    Ma T; Wang X; Wang J; Liu X; Lai S; Zhang W; Meng L; Tian Z; Zhang Y
    Front Genet; 2021; 12():726369. PubMed ID: 34721523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cuproptosis-related lncRNA signature for prognostic prediction in patients with acute myeloid leukemia.
    Zhu Y; He J; Li Z; Yang W
    BMC Bioinformatics; 2023 Feb; 24(1):37. PubMed ID: 36737692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationships of N6-Methyladenosine-Related Long Non-Coding RNAs With Tumor Immune Microenvironment and Clinical Prognosis in Lung Adenocarcinoma.
    Zhao J; Lin X; Zhuang J; He F
    Front Genet; 2021; 12():714697. PubMed ID: 34777460
    [No Abstract]   [Full Text] [Related]  

  • 16. N6-Methyladenosine-Related lncRNA Signature Predicts the Overall Survival of Colorectal Cancer Patients.
    Song W; Ren J; Yuan W; Xiang R; Ge Y; Fu T
    Genes (Basel); 2021 Aug; 12(9):. PubMed ID: 34573357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N6-methyladenosine Modification-Related Long Non-Coding RNAs are Potential Biomarkers for Predicting the Prognosis of Patients With Osteosarcoma.
    Yang K; Wang F; Li K; Peng G; Yang H; Xu H; Xiang Y; Sun H
    Technol Cancer Res Treat; 2022; 21():15330338221085354. PubMed ID: 35422168
    [No Abstract]   [Full Text] [Related]  

  • 18. Identification and validation of a seven m6A-related lncRNAs signature predicting prognosis of ovarian cancer.
    Song Y; Qu H
    BMC Cancer; 2022 Jun; 22(1):633. PubMed ID: 35676619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A signature of cuproptosis-related lncRNAs predicts prognosis and provides basis for future anti-tumor drug development in breast cancer.
    Yu H; Liu Y; Zhang W; Peng Z; Yu X; Jin F
    Transl Cancer Res; 2023 Jun; 12(6):1392-1410. PubMed ID: 37434691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and validation of the potential biomarkers based on m6A-related lncRNAs for the predictions of overall survival in the lung adenocarcinoma and differential analysis with cuproptosis.
    Gao C; Kong N; Zhang F; Zhou L; Xu M; Wu L
    BMC Bioinformatics; 2022 Aug; 23(1):327. PubMed ID: 35941550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.